NeoTRACK trial: <u>Neo</u>adjuvant <u>T</u>i<u>R</u>agolumab, <u>A</u>tezolizumab and <u>C</u>hemotherapy - dissection of IO- efficacy in NSCLC by longitudinal trac<u>K</u>ing - protocol of a non-randomised, open-label, single-arm, phase II study.

ABSTRACT:

Background

Immunotherapies targeting the programmed death receptor-1/programmed death ligand-1(PD-1/PD-L1) checkpoint have a major impact on the treatment of both resectable and advanced non-small cell lung cancer (NSCLC). Additional blockade of the T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain (TIGIT)-receptor may synergistically foster the immune-related response. Several trials are currently investigating the combination of neoadjuvant platinum-based chemotherapy and dual checkpoint inhibition prior to curative surgery. The investigator-initiated NeoTRACK trial (EU CT number: 2022-501322-38-00; ClinicalTrials.gov identifier: NCT05825625; IKF056) aims to evaluate the feasibility and safety of perioperative anti-PD-L1 (by atezo

SUBMITTER: Roesch RM 

PROVIDER: S-EPMC11956294 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature